Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMLQJ5P)

Drug Name
AMG 228 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMLQJ5P

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activation-inducible TNFR family receptor (TNFRSF18) TTG6LA7 TNR18_HUMAN Agonist [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Activation-inducible TNFR family receptor (TNFRSF18) DTT TNFRSF18 2.39E-03 -0.54 -0.7
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02437916) Safety Study of AMG 228 to Treat Solid Tumors. U.S. National Institutes of Health.
2 Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer. 2018 Sep 25;6(1):93.